Setting-Initial cost-effectiveness evaluations of Xpert MTB/RIF (Xpert) for tuberculosis (TB) diagnosis have not fully accounted for realities of implementation in peripheral settings.
INTRODUCTION
Tuberculosis (TB) is the leading single-agent infectious cause of death globally, responsible for 1.5 million deaths in 2014. 1 An estimated 3.6 million cases go unreported every year; reaching this "missing 3 million" is among the highest priorities for global TB control. 1 In 2010, the World Health Organization endorsed Xpert MTB/RIF (Xpert), a molecular TB diagnostic test that can provide results in two hours with minimal human resource requirements, higher sensitivity than sputum smear microscopy, and the ability to identify multi-drug resistant (MDR-) TB based on detected resistance to rifampin. 2, 3 Scale-up has been rapid, with more than 10 million cartridges procured under concessional pricing in over 100 countries through 2014. 4, 5 However, while sputum smear microscopy costs $1-$3 per test in most high-burden countries, 6 Xpert has been estimated to cost between $15 and $50 per test. [7] [8] [9] [10] [11] Thus, a key question is whether the improved accuracy of Xpert is worth the additional cost.
Initial economic evaluations suggested that Xpert is cost-effective, though estimations of incremental cost-effectiveness vary. 7, 8, [11] [12] [13] These earlier modeling studies largely assumed efficiently functioning laboratories that served as initial sites of Xpert scale-up. Over time, however, the focus of Xpert implementation has shifted to district and subdistrict levels, [14] [15] [16] where the cost of Xpert may be substantially higher because of lower testing volumes or additional costs associated with transport and installation. 17 Previous work in South Africa has suggested that point-of-treatment placement of Xpert could increase Xpert testing cost by 50% or more; 9 whether that additional cost, as well as the linkage between such additional cost and the potential for Xpert to improve diagnostic outcomes, generalizes to high-burden low-income settings remains uncertain.
METHODS

Ethical considerations
This study received approval from institutional review boards at Makerere University College of Health Sciences in Kampala, Uganda, and Johns Hopkins Bloomberg School of Public Health in Baltimore, MD, USA.
Overview
We nested this evaluation of Xpert costs and TB diagnoses into a larger observational study of implementing TB diagnostic algorithms in Uganda. 22 Data were collected at 18 rural and urban health facilities from 2012-2014, selected to be representative of both geography and health system level: one national referral center (not included in this analysis), four regional referral centers, nine district hospitals, and four sub-district health centers. Xpert had been implemented in seven sites (plus the national referral center) at the time of evaluation, whereas the remaining 10 sites had laboratories capable of performing sputum smear microscopy. These 10 sites provided Xpert testing only as an offsite referral test from another health center (and only rarely). Here we compared five sites where Xpert was implemented (excluding two sites that served as referral centers) against the ten sites without Xpert.
Our primary aim was to measure costs and diagnostic outcomes related to Xpert testing as actually implemented in various levels of the Ugandan healthcare system in order to explore the primary drivers of Xpert cost-effectiveness in such settings. Because we did not measure the costs or outcomes of treatment, we did not attempt to estimate cost-effectiveness in terms of cost per disability-adjusted life year (DALY) averted, but rather used cost per diagnostic outcome (diagnosis of TB or rifampin-resistant TB) as a more proximal measure for exploring the key drivers of cost-effectiveness in these settings.
Empiric costing
We estimated diagnostic costs from the health system perspective using a unit-based "ingredients" approach. This method identifies and values all inputs required to perform diagnostic testing in order to develop a unit cost for each test. At five sites with Xpert implementation (two regional hospitals, one district hospital, and two sub-district [Level IV] health centers), we collected costs of overhead, building space, equipment, staff, reagents, and consumables related to Xpert testing and smear microscopy. We used a combination of laboratory personnel interviews, budgetary documentation reviews, procurement guides, and publically available product information. Overhead costs were allocated based on proportional space required for TB testing and percentage of staff time devoted to TB testing, as appropriate. To determine allocation of costs of shared resources between Xpert testing and non-Xpert testing, we directly observed time and motion of laboratory procedures at each site. For smear microscopy, we assumed an algorithm consisting of two smears per patient. Costs and diagnostic outcomes of TB culture (performed only rarely in these sites) were excluded.
We assumed that one person would require training in Xpert use per site per year, and that Xpert cartridge procurement and transportation would equal 10% of the US$9.97 cartridge list price, based on consultation with experts in Uganda. Cost of shipping the GeneXpert four-cartridge system was incorporated as a 10.9% markup of the ex-works list price. 23 Annual maintenance of GeneXpert was based on annual warranty cost 24 with a 5 year expected lifetime, whereas we assumed annual maintenance costs of all other durable equipment and building space to be 5% of total cost each year given assumed expected lifetime of 30 years. All future costs were discounted at 3% per year. 25 Costs were measured in 2014 currency and converted to US dollars using published exchange rates.
Estimation of diagnoses made
We reviewed 12 months of TB laboratory records, including electronic Xpert instrument logs and laboratory specimen registers, for Xpert testing volume and results of Xpert and smear microscopy at each site as reported previously. 22 Laboratory results and treatment data for 100 consecutive patients who provided sputum samples were also abstracted at each site in order to establish linkages between test results and treatment initiation. In order not to underestimate the cost-effectiveness of Xpert in diagnosing smear-negative TB, we assumed that Xpert tests run without a specific reason recorded were performed for the purpose of diagnosing TB over other reasons (e.g., treatment monitoring).
Analysis of outcomes
Primary cost outcomes were the cost per Xpert test performed and the incremental cost of diagnosis of a new TB case due to Xpert. Our primary effectiveness outcome was the number of positive Xpert tests performed on individuals without known pre-existing TB. A secondary effectiveness outcome was the number of Xpert tests indicating rifampin resistance among individuals not previously documented as having MDR-TB. For each Xpert site, we calculated the mean monthly cost of Xpert testing, mean number of incremental TB diagnoses, and thus the cost per diagnosis made. Finally, we compared mean facility-level estimates of monthly diagnostic costs and number of individuals started on TB treatment between sites with and without Xpert.
Uncertainty analysis
We directly measured costs and diagnostic outcomes, and therefore did not need to use parameter values from literature. Nevertheless, our sample size of five Xpert sites still leads to uncertainty in our estimates as a reflection of other similar Ugandan clinics. To capture this uncertainty, we adopted a probabilistic approach in which we drew 10,000 samples of testing volume, Xpert unit cost (as a function of testing volume), and number of newly diagnosed TB and MDR-TB cases (as a function of testing volume). Testing volume was modeled as a gamma distribution to reflect the zero bound and right skew observed in our data. In each simulation, we calculated the diagnostic cost per Xpert test positive for TB and diagnostic cost per Xpert test positive for rifampin resistance. We also compared the costeffectiveness of TB testing in simulated sets of nine small-volume facilities (<20 tests per month) against single large-volume facilities (> 20 tests per month; mean nine times larger than small-volume facilities).
RESULTS
Unit cost of Xpert
Across the five sites evaluated, the mean unit cost of Xpert was US$21 based on an observed mean monthly volume of 54 tests per site ( Figure 1 ). Reagents (including the Xpert cartridge) and equipment comprised 93% of this unit cost, which varied from US$16 to US $58 across sites. The primary driver of this variation was testing volume, which tended to be higher in regional and district hospitals and lower in sub-district health centers. If all five facilities operated under their lowest-volume conditions observed over the 12-month periods, the estimated mean unit cost would rise from US$21 to US$65 (Table 1) .
Xpert diagnostic costs and outcomes
The estimated monthly incremental diagnostic cost of Xpert testing at each site ranged from US$590-US$2098 (Table 2). Regional and district-level hospitals had higher total costs for the overall Xpert testing program per month due to larger volumes of Xpert testing. On average, of the 54 Xpert tests per site per month, 9.6 were positive for TB and 0.5 indicated rifampin resistance, though variation across sites was substantial. The diagnostic cost per positive Xpert test on patients not known to have TB averaged US$119 (range US$80-885), whereas the diagnostic cost per positive test for rifampin resistance among those without known pre-existing resistance averaged US$1383 (range US$896-7081), reflecting the smaller number of rifampin-resistant cases diagnosed. Cost per positive diagnosis was highest in sites with lowest volumes of testing. Figure 2 presents the estimated incremental costs and diagnoses due to Xpert by comparing costs, number of diagnoses, and number started on treatment at Xpert versus non-Xpert sites. The total cost of TB diagnosis per month averaged US$1679 per Xpert site. Total TB diagnostic costs were 2.4-fold higher in clinics with Xpert testing compared to those without (US$702, based on our empiric estimate of US$1.41 per sputum smear). However, Xpert resulted in an estimated 5.3 incremental diagnoses per site per month, an incremental yield of only 12%. While treatment initiations were 31% higher in Xpert versus non-Xpert sites, rates of treatment initiation after diagnostic testing at Xpert and non-Xpert sites were similar at 87% and 89%, respectively. 
Uncertainty analysis
DISCUSSION
This economic investigation of Xpert implementation across regional, district, and subdistrict health centers in Uganda suggests that costs and impact of Xpert testing vary widely across sites and levels of the health system, with a strong dependence on testing volume. For example, the diagnostic cost per positive Xpert test ranged from US$80 in the highestvolume site to US$885 in the lowest-volume site. Xpert testing accounted for more than 60% of all diagnostic costs but was responsible for no more than 12% of new TB diagnoses. As Xpert is increasingly implemented in lower-volume settings, it may become less costeffective.
Consistent with prior studies performed under conditions of greater resource availability, 19, 26 we found that implementation of Xpert in Uganda (a country with fewer resources and outside a trial setting) led to few incremental TB diagnoses relative to the current standard based on sputum smear. We augment this understanding by correlating diagnostic outcomes with the incremental cost of Xpert, which constituted over 60% of diagnostic costs in sites utilizing Xpert. In our uncertainty analysis simulations, the median cost per new TB case detected was US$106; however, this increased when considering Xpert implementation in sites with low testing volume. These findings may help inform decision-makers about the appropriateness of Xpert deployment in different settings.
Prior analyses have estimated the mean unit cost of Xpert to vary within US$20-$30 depending on country deployed, 11 while others have also noted that testing volume is an important contributor to cost variations. 9, 10 Our analysis builds on this by describing the degree of variability that could be observed even within the same health system. This research suggests that there is likely a threshold testing volume -and thus, a threshold level of healthcare system -at which Xpert should be implemented. Such thresholds may raise concerns about trade-offs between equity and efficiency in peripheral settings, especially as some apparent cost savings from a more centralized referral system may in fact represent costs shifted away from the health system and instead toward patients who would have to travel further, wait longer for results, and delay treatment initiation. Cost-effectiveness of Xpert testing at lower-volume centers could potentially be improved with increased volume of patients referred for testing, such as through facility-based screening and other intensified case-finding initiatives. 27, 28 Alternatively, referral networks could be further developed to deliver sputum specimens efficiently to more centralized sites, 29, 30 an approach which must consider quality of available transport networks and potential for pre-treatment loss to follow-up while awaiting results. Novel lower-cost platforms for Xpert testing (e.g., Xpert Omni, 31 Alere q 32 ) may also aid in cost-effective decentralization of testing. Future research should evaluate the appropriate healthcare level for Xpert implementation in different economic and epidemiological settings, investigate the economic impact of alternative approaches in peripheral settings, and evaluate trade-offs between patient costs and healthcare system costs when placing Xpert centrally versus peripherally.
Our study has several limitations. First, we only included costs of Xpert and sputum smear microscopy in estimating diagnostic costs, excluding ancillary evaluation (e.g., chest X-ray, antibiotic trials) costs. As a result, we likely underestimate the true diagnostic program cost at both Xpert and non-Xpert sites. Second, we took as our primary effectiveness outcome the observed number of positive Xpert tests not performed on those with known TB, which may overestimate the incremental value of Xpert. Third, HIV status was not reliably logged in patient records. We were therefore unable to evaluate the differential costs and impact on diagnoses from Xpert testing within this important sub-group. 33 Finally, we measured costs from the healthcare perspective and did not incorporate patient costs. Including patient costs would increase overall estimates of diagnostic and treatment costs, though the incremental cost due to Xpert might differ according to diagnostic algorithm (e.g., whether testing is same-day).
In summary, this analysis demonstrates that Xpert diagnostic costs and impact on TB and MDR-TB diagnoses made can vary widely at different levels of the same healthcare system, with cost-effectiveness deteriorating substantially in low-volume settings. As Xpert is scaled up to sites with increasingly lower testing volumes, more attention must be paid to proper placement within the healthcare system and the development of alternative strategies to make peripheral implementation more cost-effective. Future policy guidance for Xpert and emerging TB diagnostic tests 34 should carefully consider the economic realities of testing in peripheral settings when recommending implementation strategies.
Figure 1. Unit cost of Xpert test by input type at each site
The height of each column (in bold above each column) represents the mean unit cost of Xpert at each of five sites in Uganda; the corresponding observed monthly Xpert volume is indicated in circles below each column. Different shades within each bar represent components of the unit cost. Note that Kayunga, as a district hospital, is at a lower level of the Uganda healthcare system than Arua and Fort Portal regional hospitals, but had a greater volume of tests. *The cost of reagents includes the Xpert cartridge. **Includes costs of overheads, building space, staff time, and consumables. ***Because time-motion data for Xpert testing was not collected at Arua, allocation of resources not directly related to Xpert (i.e., all but GeneXpert system and Xpert cartridge) was based on time-motion studies in Fort Portal; these resources accounted for 9% of costs per Xpert test in Fort Portal.
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Figure 2. Incremental costs and associated diagnostic and treatment impact of Xpert implementation
The left graph shows costs of diagnosis from the healthcare setting in sites without and with on-site Xpert testing, while the right graph shows corresponding outcomes: the number of cases diagnosed and number of cases started on treatment. Incremental newly diagnosed cases due to Xpert (in light blue) were estimated by applying the observed proportion of newly diagnosed cases with a preceding positive Xpert result ( Table 2 Total costs and associated diagnostic impact of Xpert implementation at each site 
